Matches in Wikidata for { <http://www.wikidata.org/entity/Q81704869> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q81704869 description "article scientifique (publié 2005)" @default.
- Q81704869 description "artikull shkencor i botuar më 01 janar 2005" @default.
- Q81704869 description "artículu científicu espublizáu en xineru de 2005" @default.
- Q81704869 description "im Januar 2005 veröffentlichter wissenschaftlicher Artikel" @default.
- Q81704869 description "scientific article published on 01 January 2005" @default.
- Q81704869 description "wetenschappelijk artikel" @default.
- Q81704869 description "наукова стаття, опублікована в січні 2005" @default.
- Q81704869 name "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 name "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 name "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 type Item @default.
- Q81704869 label "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 label "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 label "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 prefLabel "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 prefLabel "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 prefLabel "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 P1433 Q81704869-8A0B94B3-D002-4641-93BF-ADDF5B395F10 @default.
- Q81704869 P1476 Q81704869-1CCAEF6B-7989-4612-A00D-62CA4967AFE1 @default.
- Q81704869 P2093 Q81704869-0F251DE5-48FD-49E2-9F55-5BB29C45FC6B @default.
- Q81704869 P2093 Q81704869-1F1E7993-38C9-4F5C-940F-2CC76EDA7B48 @default.
- Q81704869 P2093 Q81704869-208C7803-01C1-45AE-8111-E97E37886050 @default.
- Q81704869 P2093 Q81704869-29104D36-002C-4CE9-B353-02D323B33751 @default.
- Q81704869 P2093 Q81704869-34532C20-80CA-4B72-9A76-83C4F25C49F7 @default.
- Q81704869 P2093 Q81704869-35315607-5CB6-4FAA-8C4B-1B3653E38F61 @default.
- Q81704869 P2093 Q81704869-557B8681-A447-4FF3-957F-41397D6CDC0A @default.
- Q81704869 P2093 Q81704869-5A10AB6C-B43C-4161-8F49-9BCC3B68CA6D @default.
- Q81704869 P2093 Q81704869-5A50AABF-276C-40BD-ADFC-A082F45ADABE @default.
- Q81704869 P2093 Q81704869-5DC84BC6-B03A-4E70-80D3-C9AB3E8DAA39 @default.
- Q81704869 P2093 Q81704869-5ECF68A7-52AB-4F74-BF13-1B0617D8ABA9 @default.
- Q81704869 P2093 Q81704869-B3505657-CCF5-4439-A6D5-BCA4FC4CAEEC @default.
- Q81704869 P2093 Q81704869-B5A292B4-EFDE-406D-A71A-84FDB92D0EE3 @default.
- Q81704869 P2093 Q81704869-BDF109B6-F367-4BA5-B694-31833CCE3DCE @default.
- Q81704869 P2093 Q81704869-DA692EDB-9F62-4680-8877-513222BC7E77 @default.
- Q81704869 P2093 Q81704869-E3410E37-061E-45C3-A7A9-1E6504BE7323 @default.
- Q81704869 P2093 Q81704869-E946EBAB-AC39-4815-B439-0944ACF44023 @default.
- Q81704869 P304 Q81704869-BB1D0418-0644-436F-9A5D-CBD18A925E3A @default.
- Q81704869 P31 Q81704869-DEC1A5A9-7813-4FEC-8E90-907C41A9F6F9 @default.
- Q81704869 P433 Q81704869-D1A5B688-97AC-40ED-A9A9-6B684CD6498C @default.
- Q81704869 P478 Q81704869-861E6D95-A4CD-49AC-AA8C-C940A7150203 @default.
- Q81704869 P577 Q81704869-B65EE74F-02E1-482E-8AB4-CFFA5425D4D6 @default.
- Q81704869 P698 Q81704869-3C80B4BC-FD8C-4A67-8058-67B50061F15E @default.
- Q81704869 P921 Q81704869-DB4D08F4-FCD6-46D8-BD97-32F70A0D6011 @default.
- Q81704869 P698 15865223 @default.
- Q81704869 P1433 Q4775353 @default.
- Q81704869 P1476 "Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption" @default.
- Q81704869 P2093 "Amanda Handley" @default.
- Q81704869 P2093 "Barbara Ferstl" @default.
- Q81704869 P2093 "Barbara Petzold" @default.
- Q81704869 P2093 "Bernd Spriewald" @default.
- Q81704869 P2093 "Dieter Willbold" @default.
- Q81704869 P2093 "Ellen Harrer" @default.
- Q81704869 P2093 "Jens Vollmar" @default.
- Q81704869 P2093 "Joachim R Kalden" @default.
- Q81704869 P2093 "Kathrin Eismann" @default.
- Q81704869 P2093 "Luis Mateo" @default.
- Q81704869 P2093 "Maria Tzatzaris" @default.
- Q81704869 P2093 "Marion Rittmaier" @default.
- Q81704869 P2093 "Michael Bäuerle" @default.
- Q81704869 P2093 "Paul Chaplin" @default.
- Q81704869 P2093 "Sandra Müller" @default.
- Q81704869 P2093 "Silke Bergmann" @default.
- Q81704869 P2093 "Thomas Harrer" @default.
- Q81704869 P304 "285-300" @default.
- Q81704869 P31 Q13442814 @default.
- Q81704869 P433 "2" @default.
- Q81704869 P478 "10" @default.
- Q81704869 P577 "2005-01-01T00:00:00Z" @default.
- Q81704869 P698 "15865223" @default.
- Q81704869 P921 Q2528140 @default.